Biodexa Pharmaceuticals (BDRX) investor relations material

Executive summary

• The company remains a clinical-stage biopharmaceutical firm focused on gastrointestinal oncology, with a pipeline including eRapa (FAP, NMIBC), MTX240 (GIST), and tolimidone (T1D).

• In 2025, the company licensed MTX240 from Otsuka and advanced eRapa into a Phase 3 trial for FAP, supported by CPRIT grants.

• The company completed multiple equity financings, including a $35M equity line of credit (ELOC), and raised £13.75M in 2025.

• The company continues to operate at a loss, with no recurring revenue and a focus on developing assets to proof-of-concept before partnering.

Financial highlights

• Net loss for 2025 was £6.38M, compared to £5.73M in 2024 and £7.08M in 2023.

• R&D expenses decreased 27% to £3.96M in 2025, reflecting reduced spend on preclinical and clinical programs.

• Administrative costs increased 27% to £4.84M, driven by higher professional fees and foreign exchange movements.

• Cash and cash equivalents at year-end 2025 were £8.53M, up from £1.67M in 2024.

• Accumulated deficit as of December 31, 2025 was £155.81M.

• No revenue was recognized in 2025 or 2024.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for the foreseeable future.

• Cash runway extends into Q3 2026, assuming current development plans; further financing will be required beyond that point.

• The company is actively evaluating additional financing options and potential strategic transactions.